Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Supergen (supg) -- Ignore unavailable to you. Want to Upgrade?

To: SG who wrote (89)	5/28/1999 9:29:00 PM
From: W Shakespeare	Read Replies (1) \| Respond to of 124

Actually, it is a mixed bag. On the one hand, SUPG gets the money it desperately needs to continue its drug trials. On the other hand, it is dilutive to current shareholders and the offering price is very much below the current stock price. Further, I'm not sure exactly how far that amount of money will carry SUPG given the expanded trials they keep announcing. What we really need at this point is for one of the big pharmaceutical firms to partner up with SUPG. This money will probably allow SUPG more time to put together a favorable partnership. I'm sure that SUPG does not want to negotiate a deal when the other side knows that they are running out of cash.